Azenosertib
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor
Trial Timeline
Nov 1, 2019 → May 6, 2025
NCT ID
NCT04158336About Azenosertib
Azenosertib is a phase 1 stage product being developed by Zentalis Pharmaceuticals for Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04158336. Target conditions include Solid Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05128825 | Phase 2 | Recruiting |
| NCT04814108 | Phase 2 | Completed |
| NCT04158336 | Phase 1 | Completed |
Competing Products
20 competing products in Solid Tumor